ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,302.57
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,883.53
-0.01%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alkermes PLC (ALKS)

  7. Alkermes PLC (ALKS) News

Alkermes (ALKS)

Alkermes PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALKS
DateTimeSourceHeadlineSymbolCompany
02/05/202412:00PR Newswire (US)Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo NordiskNASDAQ:ALKSAlkermes PLC
01/05/202412:00PR Newswire (US)Alkermes plc Reports First Quarter 2024 Financial ResultsNASDAQ:ALKSAlkermes PLC
24/04/202412:00PR Newswire (US)Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1NASDAQ:ALKSAlkermes PLC
17/04/202421:00PR Newswire (US)Alkermes to Report First Quarter Financial Results on May 1, 2024NASDAQ:ALKSAlkermes PLC
17/04/202421:00PR Newswire (US)Alkermes to Report First Quarter Financial Results on May 1, 2024NASDAQ:ALKSAlkermes PLC
09/04/202412:00PR Newswire (US)Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaNASDAQ:ALKSAlkermes PLC
09/04/202412:00PR Newswire (US)Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaNASDAQ:ALKSAlkermes PLC
08/04/202412:00PR Newswire (US)Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research SocietyNASDAQ:ALKSAlkermes PLC
07/03/202412:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALKSAlkermes PLC
07/03/202412:00PR Newswire (US)Alkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsNASDAQ:ALKSAlkermes PLC
27/02/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
27/02/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
27/02/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
27/02/202421:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
27/02/202421:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202421:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202421:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202421:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202422:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202422:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202422:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202422:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202422:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202422:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202421:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALKSAlkermes PLC
15/02/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALKSAlkermes PLC
15/02/202412:00PR Newswire (US)Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024NASDAQ:ALKSAlkermes PLC
 Showing the most relevant articles for your search:NASDAQ:ALKS

Your Recent History

LSE
AGL
Angle
LSE
SRSP
Sirius Petroleum
LSE
AAZ
Anglo Asian Mining
LSE
SCLP
Scancell
LSE
POS
Plexus
LSE
AAU
Ariana Resources
LSE
CHLL
Chill Brands
LSE
LLOY
Lloyds Banking
LSE
INSG
Insig Ai
LSE
HUM
Hummingbird Resources
LSE
BT.A
Bt
LSE
APTA
Aptamer
LSE
IES
Invinity Energy Systems
LSE
TERN
Tern
LSE
MIN
Minoan
LSE
BIRD
Blackbird
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved